BMO Capital Maintains Outperform on Merck & Co, Lowers Price Target to $136
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Merck & Co (NYSE:MRK) but lowers the price target from $150 to $136.
November 01, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BMO Capital has maintained its Outperform rating on Merck & Co but has lowered the price target from $150 to $136, indicating a more conservative outlook.
The maintenance of an Outperform rating suggests continued confidence in Merck's performance, but the lowered price target indicates a more cautious outlook, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100